Skip to main content
. 2018 Nov 29;9:690. doi: 10.3389/fendo.2018.00690

Table 2.

Descriptive data of controlled ovarian stimulation, oocytes, embryo transfer, and luteal phase support.

17-OH P4, nmol/l All <6 6-14 14.1-30 >30 p
Number of patients (n) 614 183 134 132 165
Protocol Antagonist (%) Long GnRH agonist (%) 63 37 51 49 58 42 61 39 81 19 <0.001
Total FSH dose (IU) 2,250 (500–7,350) 2,450 (900–6,750) 2,063 (788–7350) 2,475 (900–5025) 1,950 (500–7,350) <0.001
Stim duration (days) 10.4 ± 2.0 10.4 ± 1.9 10.6 ± 2.1 10.6 ± 2.1 9.9 ± 1.9 0.006
Final follicle count >12 mm on trigger day 10 (1–29) 10 (1–29) 9 (1–22) 9 (3–20) 10 (1–26) 0.005
Mode of triggering for final oocyte maturation
hCG (%) 58 67 72 61 35 <0.001
GnRH agonist (%) 42 33 28 39 65
Number of oocytes retrieved (n) 8 (1–28) 9 (1–23) 8 (1–26) 8 (1–24) 9 (2–28) 0.014
Number of fertilized oocytes (n) 8 (1–27) 8 (1–23) 8 (1–23) 7 (1–24) 8 (2–27) 0.033
Single embryo transfer (%) Double embryo transfer (%) 81 19 79 21 79 21 83 17 83 17 0.661
At least one top quality embryo for transfer (%) 64 66 59 70 64 0.160
Mean embryo score, SET DET 1.4 ± 0.6 1.7 ± 0.6 1.4 ± 0.6 1.7 ± 0.6 1.5 ± 0.7 1.7 ± 0.7 1.3 ± 0.5 1.6 ± 0.7 1.5 ± 0.7 1.6 ± 0.6 0.090 0.915
Day of transfer, Cleavage-stage embryo transfer (%) Blastocyst transfer (%) 72 28 72 28 72 28 77 23 68 32 0.418
Luteal phase support Vaginal progesterone only (%) + 1 bolus of hCG (%) + 2 boluses of hCG (%) Vaginal P + Gonapeptyl (%) 52 17 25 6 61 28 4 7 66 19 8 7 53 9 30 8 31 9 56 4 <0.001* <0.001 <0.001 0.353

Descriptive data is presented as mean ± SD for continuous parametric data and as median (range) for continuous non-parametric data. Categorical data is presented as percentages (%).

*

p-value describes the comparison between the chosen luteal phase support category and the combined group of all other luteal phase support categories. SI conversion factor for 17-OH P4: nmol/l = 3.03 * ng/ml.